{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:37:57Z","timestamp":1774463877041,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Australian National Health and Medical Research Council","award":["565074"],"award-info":[{"award-number":["565074"]}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ymgme.2015.03.002","type":"journal-article","created":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T17:33:02Z","timestamp":1426181582000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice"],"prefix":"10.1016","volume":"115","author":[{"given":"Helen","family":"Beard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda J.","family":"Luck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Hassiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Trim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marten F.","family":"Snel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Hopwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim M.","family":"Hemsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2015.03.002_bb0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill, New York","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgme.2015.03.002_bb0010","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ana.22092","article-title":"Mucopolysaccharidosis type IIIA: clinical spectrum and genotype\u2013phenotype correlations","volume":"68","author":"Valstar","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0015","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2006.10.005","article-title":"Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice","volume":"90","author":"Hemsley","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0025","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/j.1601-183X.2008.00413.x","article-title":"Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice","volume":"7","author":"Hemsley","year":"2008","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0030","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1460-9568.2009.06666.x","article-title":"Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease","volume":"29","author":"Hemsley","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ymgme.2009.07.013","article-title":"Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs\u2014a proof of principle study","volume":"98","author":"Hemsley","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.nbd.2011.04.014","article-title":"Enzyme replacement reduces neuropathology in MPS IIIA dogs","volume":"43","author":"Crawley","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0045","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/ejn.12557","article-title":"Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease","volume":"39","author":"Hassiotis","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.expneurol.2014.09.008","article-title":"Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods","volume":"263","author":"Marshall","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0055","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-014-9790-8","article-title":"Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain","author":"King","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2004.07.003","article-title":"Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I","volume":"83","author":"Kakkis","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2006.12.012","article-title":"Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid","volume":"91","author":"Dickson","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0070","first-page":"2520","article-title":"Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy","volume":"21","author":"Lee","year":"2007","journal-title":"F.A.S.E.B. J."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0075","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/mt.2008.9","article-title":"Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis","volume":"16","author":"Chang","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0080","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jnr.23423","article-title":"Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)","volume":"92","author":"Katz","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0085","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.expneurol.2008.10.021","article-title":"Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann\u2013Pick A disease","volume":"215","author":"Dodge","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0090","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.expneurol.2011.04.019","article-title":"Treatment of canine fucosidosis by intracisternal enzyme infusion","volume":"230","author":"Kondagari","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0095","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/hmg\/ddr175","article-title":"Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy","volume":"20","author":"Stroobants","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2015.03.002_bb0100","doi-asserted-by":"crossref","first-page":"e30341","DOI":"10.1371\/journal.pone.0030341","volume":"7","author":"Calias","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2015.03.002_bb0105","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10545-011-9341-5","article-title":"Emerging therapies for neurodegenerative lysosomal storage disorders \u2014 from concept to reality","volume":"34","author":"Hemsley","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0110","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s00415-012-6413-x","article-title":"Cerebrospinal fluid and lumbar puncture: a practical review","volume":"259","author":"Wright","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3171\/jns.1983.59.3.0369","article-title":"Recent research into the nature of cerebrospinal fluid formation and absorption","volume":"59","author":"McComb","year":"1983","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1743-8454-1-2","article-title":"Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species","volume":"1","author":"Johnston","year":"2004","journal-title":"Cerebrospinal Fluid Res."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0125","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2990.2010.01158.x","article-title":"Intracisternal enzyme replacement therapy in lysosomal storage diseases: routes of absorption into brain","volume":"37","author":"Jolly","year":"2011","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0130","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/nan.12010","article-title":"Intracisternal enzyme replacement therapy in lysosomal storage diseases: dispersal pathways, regional enzyme concentrations and the effect of post-treatment posture","volume":"39","author":"Jolly","year":"2013","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2006.05.079","article-title":"Characterization of a C57BL\/6 congenic mouse strain of mucopolysaccharidosis type IIIA","volume":"1104","author":"Crawley","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1203\/01.PDR.0000129661.40499.12","article-title":"Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice","volume":"56","author":"Gliddon","year":"2004","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/glycob\/11.1.99","article-title":"A novel missense mutation in lysosomal sulfamidase is the basis of MPS IIIA in a spontaneous mouse mutant","volume":"11","author":"Bhattacharyya","year":"2001","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2015.03.002_bb0150","series-title":"The Mouse Brain in Stereotaxic Co-ordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.ymgme.2015.03.002_bb0155","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-2999(80)90515-4","article-title":"Intrathecal morphine in mice: a new technique","volume":"67","author":"Hyldan","year":"1980","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0160","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/rcm.6861","article-title":"A simple method for early age phenotype confirmation using toe tissue from a mouse model of MPS IIIA","volume":"28","author":"Trim","year":"2014","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.expneurol.2011.04.004","article-title":"Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA","volume":"230","author":"Rozaklis","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0170","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1213\/ANE.0b013e3182536211","article-title":"The frequency and magnitude of cerebrospinal fluid pulsations influence intrathecal drug distribution: key factors for interpatient variability","volume":"115","author":"Hsu","year":"2012","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0175","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.anorl.2011.03.002","article-title":"Anatomy and physiology of cerebrospinal fluid","volume":"128","author":"Sakka","year":"2011","journal-title":"Eur. Ann. Otorhinolaryngol. Head Neck Dis."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0180","series-title":"Peptide Drug Delivery to the Brain","article-title":"Transnasal and intraventricular delivery of drugs","author":"Pardridge","year":"1991"},{"key":"10.1016\/j.ymgme.2015.03.002_bb0185","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1096\/fj.04-1711fje","article-title":"Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroid plexus water channel Aquaporin-1","volume":"19","author":"Oshio","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0190","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tvjl.2005.07.021","article-title":"The function, composition and analysis of cerebrospinal fluid in companion animals: part I \u2014 function and composition","volume":"172","author":"Di Terlizzi","year":"2006","journal-title":"Vet. J."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0195","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.expneurol.2010.07.023","article-title":"Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease","volume":"225","author":"Cabrera-Salazar","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0200","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ana.22262","article-title":"Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis","volume":"69","author":"Tsuji","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0205","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ymgme.2012.05.005","article-title":"Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II","volume":"107","author":"Higuchi","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.03.002_bb0210","article-title":"Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis","author":"Vuillemenot","year":"2014","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215000669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215000669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T22:41:43Z","timestamp":1566427303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719215000669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1096719215000669"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.03.002","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}